arrow
R

Ryon P. Graf

foundation medicine
H指数:30
被引数:3,976

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer

探索与转移性去势抵抗性前列腺癌患者从talazoparib单药治疗中获益延长或耐药相关的肿瘤基因组学研究

2026-09-290
OA
High-Specificity Detection of Ultraviolet Mutational Signatures in Circulating Tumor DNA for Diagnostic Classification of Cutaneous and Unknown Primary Tumors using FoundationOne Liquid CDx

使用FoundationOne Liquid CDx对循环肿瘤DNA进行高特异性检测,以诊断分类皮肤癌和原发部位不明的肿瘤中的紫外线突变特征。

2025-08-200
OAAI
Technical Advance, FoundationOne CDx and FoundationOne Heme Detect Epstein-Barr Virus with High Sensitivity and Specificity

技术先进,FoundationOne CDx和FoundationOne Heme以高灵敏度和特异性检测EB病毒

2025-07-230
OAAI
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
2024-10-050
OAAI
Pan-tumor validation of a NGS fraction-based MSI analysis as a predictor of response to Pembrolizumab
2024-09-140
OAAI
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (June, 10.1007/s10549-024-07427-2, 2024)
2024-07-130
OAAI
Evaluation of circulating tumor DNA kinetics as a prognostic biomarker for overall survival in metastatic castrate resistant prostate cancer using a novel methylation sequencing research assay
2023-04-040
PRE